Kura Oncology, Inc.(KURA)

$8.61▲0.27 (3.24%)

Kura Oncology, Inc.(KURA)

NASDAQ

$8.61▲0.27 (3.24%)

Overview Intelligence Chart Fundamentals Key Metrics Earnings Growth Analysts Financials Insiders Institutional

Analyst Sentiment

Analysts lean bullish — 93% recommend buying.

Consensus Rating

Buy

15 analysts·Moderate coverage

93%

Rating Distribution

Strong Buy

00%

Buy

1493%

Hold

17%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 228% higher.

Bear Case

$15.00

+74%

Consensus

$28.20

+228%

Bull Case

$40.00

+365%

Price Range15 analysts

Low

Consensus

High

$15.00

$40.00

Current Target

Current Price

$8.61

Upside to Target

$19.59

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+108.78%

EPS—

FY2028

Rev+55.96%

EPS—

FY2029

Rev+93.41%

EPS—

Earnings Surprises

Recent Analyst Actions

Mar 13, 2026UBS

Kura Oncology (KURA) PT Lowered to $15 at UBS

Target:$15.00

+74.5%from $8.60

Jan 13, 2026Leerink Partners

Kura Oncology price target lowered to $20 from $25 at Leerink

Target:$20.00

+121.6%from $9.03

Nov 24, 2025Barclays

Kura Oncology price target raised to $28 from $11 at Barclays

Target:$28.00

+150.7%from $11.17

Nov 14, 2025Wedbush

Kura Oncology price target raised to $38 from $36 at Wedbush

Target:$38.00

+228.5%from $11.57

Nov 14, 2025H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)

Target:$40.00

+239.6%from $11.78

Mar 6, 2025UBS

Kura Oncology price target lowered to $14 from $27 at UBS

Target:$14.00

+81.8%from $7.70

Nov 22, 2024Stifel Nicolaus

Kura Oncology (KURA) PT Lowered to $11 at Stifel

Target:$11.00

+1.9%from $10.80

Oct 24, 2024UBS

UBS Starts Kura Oncology (KURA) at Buy

Target:$27.00

+58.6%from $17.02

Oct 14, 2024Stifel Nicolaus

Stifel Downgrades Kura Oncology (KURA) to Hold

Target:$19.00

+2.3%from $18.58

Jun 25, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)

Target:$32.00

+51.8%from $21.08

May 23, 2024Stifel Nicolaus

Stifel Reiterates Buy Rating on Kura Oncology (KURA)

Target:$28.00

+30.7%from $21.43

Dec 22, 2023Mizuho Securities

Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst

Target:$26.00

+88.3%from $13.81

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance